Non-small-cell lung cancer (NSCLC) is one of the most dynamic oncology indications and a key area of focus for drug developers. Immune checkpoint inhibitors have transformed the management of advanced NSCLC. In late 2018, Tecentriq (Roche / Genentech / Chugai) was the second immune checkpoint inhibitor to enter the coveted first-line metastatic setting, after Keytruda (Merck & Co.). Competition is set to intensify as multiple combination therapies based on immune checkpoint inhibition gain approval and enter the clinic. In addition, novel biomarker-driven therapies such as next-generation EGFR and ALK inhibitors are vying for a share of this increasingly crowded and competitive market.
- How large are the drug-treatable NSCLC populations, and how will drug-treatment rates change over time in market-relevant populations?
- How will recent and expected market approvals shape the uptake of immune checkpoint inhibitors for the first-line treatment of metastatic NSCLC? Which agents and combinations will dominate this commercially lucrative disease setting?
- What pipeline products are most promising, and what uptake and sales could they secure in NSCLC? What therapies of note are progressing in earlier phases of development?
- What are the key market drivers and constraints in NSCLC, and how will the market evolve over the forecast period?
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: 16 country-specific interviews with experts and 210 country-specific surveys with medical oncologists treating NSCLC.
Epidemiology: Diagnosed and recurrent incidence of adenocarcinoma, squamous cell carcinoma, large cell carcinoma and other, and unverified NSCLC.
Population segments in market forecast: Stage IB/II, stage III, first line, second line, and third line for metastatic adenocarcinoma, squamous cell carcinoma, large cell carcinoma and other, and unverified NSCLC.
Emerging therapies: Phase I/II: 13 drugs; Phase III / PR: 17 drugs.